High-efficacy disease-modifying therapies for MS — natalizumab, ocrelizumab, ofatumumab, alemtuzumab, cladribine, and ublituximab — represent a paradigm shift in MS treatment. They achieve relapse reductions of 60-80% (vs ~30% with platform DMTs), substantially reduce disability progression, and are increasingly used first-line for highly active relapsing-remitting MS, secondary progressive MS, and primary progressive MS. These agents carry distinct risks — opportunistic infections, malignancy, autoimmune complications — that demand careful patient selection and monitoring. This page covers the high-efficacy DMTs.

Anti-CD20 Monoclonal Antibodies

Ocrelizumab (Ocrevus)

  • Mechanism: humanized monoclonal antibody against CD20 on B cells; depletes B cells (and some CD20+ T cells).
  • Dosing: 600 mg IV every 6 months (first dose split as 300 mg + 300 mg 2 weeks apart).
  • Uses: RRMS, active SPMS, and — uniquely — primary progressive MS (only FDA-approved DMT for PPMS).
  • Side effects: infusion reactions (premedicate with steroid, antihistamine, acetaminophen); infections (respiratory, urinary, herpes zoster reactivation); hypogammaglobulinemia with chronic use; possible increased malignancy (breast cancer signal in trials — confirmed risk debated).
  • Pregnancy: 6-12 months before conception ideal; B-cell depletion may affect fetal immune system.
  • Vaccinations: complete 4-6 weeks before initiation; subsequent vaccines effective but reduced response.

Ofatumumab (Kesimpta)

  • Mechanism: fully human anti-CD20 monoclonal antibody; subcutaneous administration.
  • Dosing: 20 mg SC weekly for first month, then 20 mg SC monthly.
  • Uses: RRMS.
  • Advantage over ocrelizumab: home injection vs IV infusion; reduced infusion reactions.
  • Side effects: similar to ocrelizumab (B-cell depletion); injection site reactions; infections.

Ublituximab (Briumvi)

  • Mechanism: chimeric anti-CD20 monoclonal antibody.
  • Dosing: shorter IV infusion than ocrelizumab; 150 mg IV first dose, 450 mg 2 weeks later, then 450 mg every 6 months.
  • Uses: RRMS.
  • Similar B-cell depletion mechanism; clinical positioning still being established.

Natalizumab (Tysabri)

Mechanism

  • Humanized monoclonal antibody against α4-integrin (VLA-4) → blocks lymphocyte transmigration across BBB.
  • Highly effective for relapses and MRI activity.

Dosing

  • 300 mg IV every 4 weeks (standard).
  • Extended interval dosing (every 6-8 weeks) explored for reducing PML risk in long-term patients.

Side Effects

  • Progressive multifocal leukoencephalopathy (PML): most feared risk; caused by JC virus reactivation.
  • Risk increases with: duration >2 years, JCV antibody positive (especially high titer), prior immunosuppression.
  • JCV antibody-negative patients: very low PML risk.
  • JCV antibody-positive with >2 years natalizumab: substantial PML risk (~1%).
  • Other: infusion reactions, hepatic enzyme elevation, anti-natalizumab antibodies.

JCV Risk Stratification and Management

  • Pre-treatment JCV antibody (and JCV antibody index for positive patients).
  • JCV-negative: very low PML risk; recheck JCV serostatus every 6 months on therapy (seroconversion can occur).
  • JCV-positive, low antibody index: intermediate risk; risk rises with duration; counsel accordingly.
  • JCV-positive, high antibody index, >24 months on therapy, prior immunosuppression: highest risk category; weigh switching to an anti-CD20 or other alternative.
  • Extended-interval dosing (every 6 weeks): appears to reduce PML risk in JCV-positive patients while preserving efficacy in many; consider in higher-risk patients.
  • MRI surveillance schedule individualized to risk category; more frequent imaging in higher-risk patients.

Place in Therapy

  • Highly active RRMS, especially in JCV-negative patients.
  • “Bridge” therapy in pregnancy planning (rebound risk if discontinued).
  • Treatment-resistant RRMS where B-cell depletion not preferred.

Alemtuzumab (Lemtrada)

Mechanism

  • Humanized anti-CD52 monoclonal antibody.
  • Profound depletion of mature T and B cells; subsequent immune reconstitution.
  • “Induction” therapy: 2 short courses (12 mg/day × 5 days at baseline, then 3 days at 12 months); response can last years without further treatment.

Side Effects

  • Infusion reactions: significant (premedicate with steroid, antihistamine, antipyretic).
  • Secondary autoimmune diseases: most clinically significant complication.
    • Autoimmune thyroid disease (~30%; Graves, hypothyroidism).
    • ITP (~1%; can be severe).
    • Goodpasture / anti-GBM disease (rare but life-threatening).
    • Other autoimmune conditions.
  • Risk Evaluation and Mitigation Strategy (REMS): monthly CBC, urinalysis, creatinine, thyroid testing for at least 4 years post-treatment.
  • Increased opportunistic infections; herpes prophylaxis around treatment.
  • Listeria infection reported.

Place in Therapy

  • Refractory RRMS in patients accepting risk-benefit.
  • Most often used in patients failed by multiple prior DMTs.
  • Restricted in some markets due to FDA label changes (cardiovascular events, autoimmune complications).

Cladribine (Mavenclad)

Mechanism

  • Purine nucleoside analog; selectively kills lymphocytes (preferential lymphocyte effects via DCK enzyme).
  • Sustained immune reconstitution.

Dosing

  • Two short courses 1 year apart, then long observation.
  • Treatment-free after 2 years for many patients.

Side Effects

  • Lymphopenia (anticipated effect).
  • Herpes zoster reactivation; antiviral prophylaxis.
  • Hepatic enzyme elevation.
  • Possible malignancy signal (low incidence).
  • Pregnancy: 6 months washout before conception; both male and female partners.

Hematopoietic Stem Cell Transplant (HSCT)

  • Autologous HSCT: “reboot” the immune system.
  • For highly active treatment-refractory RRMS.
  • High initial morbidity, mortality; substantial expertise needed.
  • Emerging evidence of durable response in selected patients.
  • Specialized MS-HSCT centers required.

Emerging Anti-B-cell and Other Therapies

  • Bruton tyrosine kinase (BTK) inhibitors: investigational (tolebrutinib, evobrutinib, fenebrutinib, remibrutinib); modulate B cells without depleting them.
  • Tolebrutinib trials: ongoing in RRMS and progressive MS.
  • Anti-CD40L (frexalimab): emerging.
  • EBV-targeted therapy: investigational (atara, others) — emerging from data showing EBV’s role in MS etiology.

Acute Relapse Management

  • Methylprednisolone 1000 mg IV daily × 3-5 days: standard for moderate-severe relapse.
  • Oral prednisone 1000-1250 mg × 3-5 days: bioequivalent alternative.
  • Plasmapheresis: for severe steroid-refractory relapse.
  • IVIG: occasionally used.
  • Steroid taper rarely needed.
  • Acute relapse treatment does NOT modify long-term outcomes; DMTs do.

Symptomatic Management Crossover

(See dedicated MS symptomatic management page.)

  • Fatigue: amantadine, modafinil, methylphenidate.
  • Spasticity: baclofen, tizanidine, dantrolene, intrathecal baclofen.
  • Bladder: anticholinergics, mirabegron, botulinum toxin, sacral nerve stim.
  • Walking: dalfampridine (4-aminopyridine).
  • Pseudobulbar affect: dextromethorphan/quinidine.
  • Tremor: clonazepam, propranolol; DBS.

🔍 Did You Know?

The recognition that JC virus seropositivity dramatically stratifies natalizumab PML risk has been one of the most important pharmacosurveillance advances in modern neurology. Progressive multifocal leukoencephalopathy (PML), caused by reactivation of JC polyomavirus in the brain, is a feared complication of natalizumab. The breakthrough was the development of JCV antibody testing — patients can be quickly tested for prior JCV exposure. JCV antibody-NEGATIVE patients have very low PML risk (~0.07/1000 patient-years); among JCV antibody-POSITIVE patients, risk rises with higher JCV antibody index, longer natalizumab exposure (especially >24 months), and prior immunosuppression. The absolute risk is substantially higher than in JCV-negative patients but is far lower than 10% in most modern risk-stratification models, and extended-interval dosing (every 6 weeks) appears to further reduce PML risk while maintaining efficacy in many patients. The order-of-magnitude risk stratification has fundamentally changed how natalizumab is prescribed: JCV-negative patients can use natalizumab long-term with relative confidence; JCV-positive patients are typically transitioned to anti-CD20 therapy (ocrelizumab, ofatumumab) within 1-2 years to limit PML exposure. Newer strategies include extended-interval dosing (every 6-8 weeks) for JCV-positive patients to reduce PML risk while maintaining efficacy. The lesson generalizes: pharmacovigilance based on biomarkers can transform an “unacceptable risk” drug into a manageable one, and similar approaches have been applied to other high-risk MS DMTs (dimethyl fumarate + JCV, fingolimod + JCV) and other conditions. For practicing neurologists, the JCV antibody test should be ordered before any natalizumab initiation and at least annually during treatment.

Pitfalls and Pearls

  • Anti-CD20 mAbs: ocrelizumab, ofatumumab, ublituximab; deplete B cells.
  • Ocrelizumab: only DMT for PPMS; IV every 6 months.
  • Ofatumumab: SC home injection; convenience advantage.
  • Hypogammaglobulinemia: monitor with B-cell depleters; consider IVIG if severe.
  • Natalizumab: most effective for relapses; α4-integrin blockade.
  • PML risk: JCV antibody-positive + duration >2 years; substantial.
  • JCV antibody testing: pre-treatment + annual; stratifies natalizumab risk.
  • Alemtuzumab: induction; profound depletion; secondary autoimmunity (thyroid, ITP, Goodpasture) — REMS monitoring 4 years.
  • Cladribine: short oral courses; lymphopenia; herpes zoster prophylaxis.
  • HSCT: emerging for refractory MS; specialized centers.
  • Acute MS relapse: methylprednisolone 1000 mg IV × 3-5 days.
  • DMTs do not treat acute relapses; steroids do.
  • Early high-efficacy DMT: increasingly first-line for highly active disease.
  • Pregnancy: B-cell depleters 6-12 months before conception; cladribine 6 months.
  • Live vaccines: complete before high-efficacy DMT.
  • Bridge therapy: natalizumab discontinuation rebound; transition planning.
  • BTK inhibitors: emerging therapy class for both RRMS and progressive MS.

References

  1. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis (OPERA I/II). N Engl J Med. 2017;376(3):221-234.
  2. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis (AFFIRM). N Engl J Med. 2006;354(9):899-910.
  3. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
  4. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis (ASCLEPIOS). N Engl J Med. 2020;383(6):546-557.
  5. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy. Lancet. 2012;380(9856):1829-1839.
  6. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426.